Wilsey Asset Management Inc Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Wilsey Asset Management Inc reduced its stake in Gilead Sciences by 0.28% during the most recent quarter end. The investment management company now holds a total of 95,892 shares of Gilead Sciences which is valued at $9,425,225 after selling 265 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Apr 11, 2016.Gilead Sciences makes up approximately 6.63% of Wilsey Asset Management Inc’s portfolio.

Gilead Sciences opened for trading at $98.53 and hit $98.98 on the upside on Friday, eventually ending the session at $98.29, with a gain of 0.10% or 0.1 points. The heightened volatility saw the trading volume jump to 89,10,623 shares. Company has a market cap of $134,347 M.

Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx boosted its stake in GILD in the latest quarter, The investment management firm added 9,765 additional shares and now holds a total of 332,794 shares of Gilead Sciences which is valued at $32,710,322. Gilead Sciences makes up approx 0.74% of Exxonmobil Investment Management Inc Tx’s portfolio.Creative Planning boosted its stake in GILD in the latest quarter, The investment management firm added 33,690 additional shares and now holds a total of 297,292 shares of Gilead Sciences which is valued at $28,489,492. Gilead Sciences makes up approx 0.22% of Creative Planning’s portfolio.Mai Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,014 additional shares and now holds a total of 27,685 shares of Gilead Sciences which is valued at $2,653,054. Gilead Sciences makes up approx 0.22% of Mai Capital Management’s portfolio.Lgt Capital Partners Ltd. boosted its stake in GILD in the latest quarter, The investment management firm added 25,410 additional shares and now holds a total of 126,710 shares of Gilead Sciences which is valued at $12,142,619. Gilead Sciences makes up approx 2.19% of Lgt Capital Partners Ltd.’s portfolio.Foundry Partners reduced its stake in GILD by selling 52,233 shares or 58.53% in the most recent quarter. The Hedge Fund company now holds 37,010 shares of GILD which is valued at $3,546,668. Gilead Sciences makes up approx 0.36% of Foundry Partners’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.